Aurinia Pharmaceuticals Files Proxy Materials
Ticker: AUPH · Form: DEFA14A · Filed: Apr 29, 2025 · CIK: 1600620
| Field | Detail |
|---|---|
| Company | Aurinia Pharmaceuticals Inc. (AUPH) |
| Form Type | DEFA14A |
| Filed Date | Apr 29, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, shareholder-meeting, sec-filing
TL;DR
AURINIA files proxy docs, shareholder vote coming up.
AI Summary
Aurinia Pharmaceuticals Inc. filed a Definitive Additional Materials proxy statement on April 29, 2025. The filing pertains to the company's proxy materials, indicating a shareholder meeting or vote is approaching. The company is based in Edmonton, Alberta, Canada, and operates in the pharmaceutical preparations industry.
Why It Matters
This filing signals upcoming shareholder decisions or votes, which could impact the company's governance and strategic direction.
Risk Assessment
Risk Level: low — This is a routine filing of proxy materials, not indicating any immediate financial or operational risks.
Key Players & Entities
- Aurinia Pharmaceuticals Inc. (company) — Registrant
- 0001600620-25-000036 (filing_id) — Accession Number
- 20250429 (date) — Filing Date
FAQ
What type of SEC filing is this?
This is a DEFA14A filing, specifically 'Definitive Additional Materials' for Aurinia Pharmaceuticals Inc.
When was this filing made?
The filing was made on April 29, 2025.
What is the company's primary business?
Aurinia Pharmaceuticals Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
Where is Aurinia Pharmaceuticals Inc. located?
The company's business and mailing address is in Edmonton, Alberta, Canada.
What does a DEFA14A filing typically relate to?
A DEFA14A filing is a proxy statement, used to solicit shareholder votes for company matters such as annual meetings, director elections, or other corporate actions.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 29, 2025 regarding Aurinia Pharmaceuticals Inc. (AUPH).